AGP Executive Report
Last update: 8 hours agoAI in Pharmacy Training: A new PeerJ study finds community pharmacists are aware of AI but often lack the knowledge and infrastructure to use it—while patients increasingly arrive with AI-sourced, highly specific questions. PBM Reform vs. Closures: Even with 2026 PBM reform momentum, community pharmacies are still shutting down as patients shift to mail order and other nontraditional channels. Hypertension Breakthrough: The FDA approved AstraZeneca’s baxdrostat (BAXFENDY) as an add-on for adults with uncontrolled blood pressure on background therapy, adding a new aldosterone-synthesis option. Urology Trial Updates: Break Wave ultrasonic lithotripsy met key safety and efficacy goals in the SOUND trial, and EMBARK post-hoc data suggest longer treatment holidays with enzalutamide plus leuprolide. Medicare Drug Prices: The Supreme Court rejected drugmaker challenges to Medicare’s negotiated price program, keeping the discounts in place. Legal Crosscurrent: In the Luigi Mangione case, a judge ruled some backpack items will be excluded, while other key items—including the alleged murder weapon and writings—can be used.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result.
Perspectify News
![<![CDATA[How Pharma is Adjusting Strategies for Changing Dynamics at FDA]]>](https://cdn.sanity.io/images/0vv8moc6/pharmexec/6e350d70ab4004975f2a3127af4f347c2cb4f74f-1280x720.jpg)
![<![CDATA[Politics, Capital Markets, Misinformation and the Impact on Biotech: Q&A with Jeremy Levin]]>](https://cdn.sanity.io/images/0vv8moc6/pharmexec/772c2fe049e7f577f88de372641f78c12a57ff1c-1920x1080.jpg)
